EMA/52884/2014

European Medicines Agency decision

P/0059/2014

of 7 March 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475) (EMEA-001474-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

European Medicines Agency decision

P/0059/2014

of 7 March 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475) (EMEA-001474-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc on 2 May 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 February 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475), powder and solvent for solution for injection/infusion, solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475), powder and solvent for solution for injection/infusion, solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475), powder and solvent for solution for injection/infusion, solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Merck Sharp & Dohme (Europe), Inc, Clos du Lynx 5, 1200 - Brussels, Belgium.

Done at London, 7 March 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/742450/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001474-PIP01-13

Scope of the application

Active substance(s):

Anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475)

Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)

Pharmaceutical form(s):

Powder and solvent for solution for injection/infusion

Solution for injection/infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc submitted for agreement to the European Medicines Agency on 2 May 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 17 July 2013.

Supplementary information was provided by the applicant on 25 November 2013. The applicant proposed modifications to the paediatric investigation plan.

A meeting with the Paediatric Committee took place on 13 February 2014.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 14 February 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- for powder and solvent for solution for injection/infusion and solution for injection/infusion, for intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)

2.1.1. Indication(s) targeted by the PIP

- Treatment of advanced, untreated or previously treated, malignant melanoma in children from 12 year old to less than 18 years of age;
- Treatment as monotherapy of a PD-L1 positive paediatric malignant solid tumour in children from 6 months to less than 18 years of age.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

- Powder and solvent for solution for injection/infusion;
- Solution for injection/infusion.

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	1	**Study 1:** In vitro study of MK-3475 targets in paediatric tumours.

Area	Number of measures	Description
Clinical studies	2	**Study 2:** Multi-centre, open-label, single-arm trial to evaluate pharmacokinetics, pharmacodynamics, toxicity, safety and activity of MK-3475 in paediatric patients from 6 months to less than 18 years with an advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumour or lymphoma, including an expansion phase. **Study 3:** Randomized, controlled trial to evaluate the safety and efficacy of MK-3475 in paediatric patients from 6 months to less than 18 years of age with a PD-L1 positive solid malignant tumour selected based on results of measures 1 and 3.
Extrapolation, modelling & simulation studies	0	Not applicable.
Other studies	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes